Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ivabradine
Drug ID BADD_D01218
Description Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a "pure" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.
Indications and Usage Ivabradine's indication by the FDA is to reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤35%, who are in sinus rhythm with resting heart rate ≥70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use.
Marketing Status Prescription
ATC Code C01EB17
DrugBank ID DB09083
KEGG ID D07165
MeSH ID D000077550
PubChem ID 132999
TTD Drug ID D0S9QA
NDC Product Code 70518-3309; 55513-813; 65977-0116; 55513-800; 55513-810
Synonyms Ivabradine | 7,8-Dimethoxy-3-(3-(((4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2H-benzazepin-2-one | S 16257 | S-16257 | S16257 | S 16257-2 | S 16257 2 | S 162572 | S-16257-2 | S162572 | S-16260-2 | S162602 | S 16260-2 | S 16260 2 | S 162602 | Corlanor
Chemical Information
Molecular Formula C27H36N2O5
CAS Registry Number 155974-00-8
SMILES CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)CC3CC4=CC(=C(C=C34)OC)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Chest discomfort22.02.08.001; 08.01.08.019; 02.02.02.0090.000303%Not Available
Chest pain08.01.08.002; 02.02.02.011; 22.02.08.0030.001314%Not Available
Chills15.05.03.016; 08.01.09.0010.000202%
Conduction disorder02.03.01.0080.000202%
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Cough22.02.03.0010.000809%
Death08.04.01.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Diplopia06.02.06.002; 17.17.01.0050.000202%Not Available
Discomfort08.01.08.003--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.0040.003537%
Dizziness postural24.06.02.008; 17.02.05.004; 02.01.02.0050.000202%Not Available
Drug hypersensitivity10.01.01.001--Not Available
Dyspepsia07.01.02.0010.000404%
Dysphagia07.01.06.0030.000404%
Dyspnoea22.02.01.004; 02.01.03.0020.002021%
Dysuria20.02.02.0020.000202%
Ear disorder04.03.01.001--Not Available
Electrocardiogram QT prolonged13.14.05.0040.000910%
Eosinophilia01.02.04.001--
Erythema23.03.06.001--Not Available
Eye disorder06.08.03.0010.000202%Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.0140.001617%Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.0250.000202%
Gallbladder disorder09.03.02.0010.000202%Not Available
Gastrooesophageal reflux disease07.02.02.0030.000202%
Gastrointestinal disorder07.11.01.0010.000303%Not Available
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages